Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Inder Kaul; Sharon Sawchak; Christoph U Correll; Rishi Kakar; Alan Breier; Haiyuan Zhu; Andrew C Miller; Steven M Paul; Stephen K Brannan